PubMed1989
Inflammatory disease such as prostatitis and prostatovesiculitis, can affect the fertility potential of the male population. In this study, the Authors tested the therapeutical efficacy of a second generation quinolone, enoxacin, in patients suffering from vesicular and/or prostatic inflammations. This drug has been shown to diffuse into the prostatic fluid, achieving therapeutical concentrations either in acute or chronic pathological conditions. Thirty infertile patients referring to our Andrology Center and showing seminal signs (leukocytes, abnormal sperm forms, chemical and physical alterations, etc) of genital tract inflammations were found to have positive sperm culture for enoxacin-sensitive strains. Further investigations (echotomography) showed that they were affected by prostatic and/or vesicular subacute chronic inflammations. The mean age was 32.2 (range 20-36) ys. All the patients discontinued any previous treatment for at least 90 days. Enoxacin was administered at the dose of 300 mg b.i.d. for two cycles of 10 days each, with intervals of 20 days. At the beginning and at the end of the treatment (days 0 and 60), semen analysis and culture were performed. A paired-T test was employed for the statistical evaluation of data. 26.6% of patients ad an altered fluidification before treatment. Only 10.0% of them showed the same sign after treatment. A condition of hyperviscosity was present in 50% and 16.6% of patients before and after treatment respectively. Likewise, an elevated number of leukocytes (greater than 10(6)/ml) occurred in the ejaculates of 43.3% of patients and in 23.3% after enoxacin treatment. Enoxacin treatment was efficacious in 89.2% of cases, in presence of either Gram positive or Gram negative bacteria.(ABSTRACT TRUNCATED AT 250 WORDS)